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Selling Sickness: How the World’s Biggest Pharmaceutical
Companies are Turning Us All into Patients. By Ray Moynihan &
Alan Cassels. Vancouver/Toronto: Greystone Books. 2005. 272 pp.
ISBN 1553651316.
Ray Moynihan and Alan Cassels’s Selling Sickness is a welcome and
accessible exposé of profit-driven pharmaceutical companies and
their extensive influence in selling sickness to the “healthy well.” The
authors argue that “the pharmaceutical industry is working behind the
scenes to help define and design the latest disorders and dysfunctions
in order to create and expand markets for their newest medicines” (p.
vii). They contend that this process turns “too much ordinary life into medical illness, in
order to expand markets for medications” (p. xix). The authors reveal how so-called sick-
nesses, ranging from high cholesterol to female sexual dysfunction, are invented and mar-
keted, in order to sell their corresponding medicinal cures. 
In aggregate, the ten chapters explore how the pharmaceutical complex makes use of
advertisers, celebrity endorsers, patient groups, medical professionals and associations,
and even federal regulators, to ensure that their drugs get sold. The strengths of this vol-
ume are its journalistic style, accessibility, and breadth.
According to the authors of this study, medical conditions have been routinely broad-
ened so as to increase the number of possible candidates for prescription medications. For
instance, the number of depressed persons has been highly inflated with revised defini-
tions of depression; ADD has been increasingly diagnosed in adults; and personality qual-
ities like shyness are now explained as social anxiety disorders. Other illnesses such as
high cholesterol are not really illnesses in and of themselves. Rather, as the authors
explain, they may be indicators or risk factors for future illnesses, but only when com-
bined with other indicators. Defining high cholesterol as an illness promotes the fear that
high cholesterol is synonymous with heart disease and allows pharmaceutical companies
like Pfizer to expand its market to the healthy and insured in order to profit from their
best selling drug Lipitor. As the definitions of disorders expand and, as we are offered
more and more drugs to deal with them, we are all more readily interpellated into the sub-
jectivity of sickness.
In order to broaden their markets by expanding the definitions of sickness, pharma-
ceutical companies often work with their “thought-leaders,” prestigious academics and
researchers who are “on drug company payrolls as advisers and paid speakers” (p. 6). Drug
companies employ celebrities and “real people” to proffer their ailments and their atten-
dant drug cures. In a chapter discussing menopause and entitled “Working with
Celebrities,” the authors discuss the prevalence of well-known stars such as Cybil Shepard
and Lauren Hutton who have publicized their experiences with menopause and their pre-
ferred pharmaceutical treatments, without disclosing their paid affiliation with the spon-
soring drug companies. Celebrities are paid handsomely for their endorsements and yet
they are not beholden to the same FDA regulations as the drug companies. Celebrities are
not the only ones on the payroll. The chapter, “Partnering with Patients: Attention Deficit
Disorder,” tells us that patient advocacy groups such as Children and Adults with
Attention-Deficit/Hyperactivity Disorder (CHADD) receive much of their funding from
pharmaceutical companies like Shire, the makers of Adderal. In return, these patient advo-
cacy groups are often called upon to represent “real people” in advertisements and to raise
awareness of their disorders and its drug treatments. 
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Doctors, along with their professional organizations and regulatory bodies, are also
held in the grip of pharmaceutical companies as described in “Doughnuts for Doctors,” a
chapter on depression, which explores the pharmaceutical industries’ intimate relation-
ships with doctors. The chapter examines the role of pharmaceutical representatives and
the fact that these relationships result in higher prescription rates. (Beginning January 1 of
this year, the pharmaceutical industry has instituted a voluntary moratorium on giving to
medical professionals.) Moreover, the study reveals how the drug companies have fostered
an entangled relationship with professional organizations like the powerful American
Psychological Association through conference sponsorship. 
As the authors contend, “Industry does not crudely buy influence with individuals and
organizations—rather its largesse is handed out to those considered to be most commer-
cially helpful” (p. 171). Shockingly, the Federal Drug Administration (FDA) is funded by
the very drug companies that it is charged with regulating. The authors tell the story of
Lotronex, a drug that was developed to treat irritable bowel syndrome and was approved
by the FDA, then taken off the market when it was found to be harmful to patients, and
then was subsequently returned to the market in response to the outcry from patient
groups. In this and other cases, Moynihan and Cassels reveal the inner workings of the
FDA, detailing how many in supervisory positions acquiesce to the desires of the pharma-
ceutical companies and their sponsored patient groups, even going so far as to bury
research that shows the harms of the medications that they approve. 
Interestingly, most of the “illnesses” or “disorders” discussed in this study involve
women. Whether it be conditions such as depression, social anxiety or irritable bowel syn-
drome or other conditions specifically concerned with the workings of the female body
such as menopause, pre-menstrual dysphonic disorder, osteoporosis, and female sexual
dysfunction, women seem to be the primary target of pharmaceutical campaigns. The
authors note that “there is a complex interplay of images and ideas back and forth between
society and the world of medicine, fed by deep-seated and wide-spread anxieties about
ageing, femininity and sexuality” (p. 48). Unfortunately, the significance of the female
body as always already “ill” is not adequately addressed, nor is the reasoning behind why
female dysfunctions may be easier to “sell” than sex/gender neutral dysfunctions. Is it
because women are the primary consumers of healthcare? And how did that come to be?
Are women conditioned by the medical profession to see their body’s functioning as
abnormal? The reader is left uncertain as to why the female and her body are prime targets
for constructed illnesses and their pharmaceutical cures. 
Many in communication studies, including scholars of health communication, critical
communication, and policy and media studies, will find this volume useful for their own
work as well as an accessible text for their students. Moynihan and Cassels provide a
wealth of information in a concrete and accessible fashion. The short chapters complement
one another and work to construct a holistic view of the selling of sickness. Although the
concluding chapter on “What Can We Do?” is relatively brief, the fact remains that we
must all be critical consumers of sickness and dedicated caretakers of our own health.
Reading Selling Sickness reveals why this is absolutely necessary.
Kristin A. Swenson, Butler University, U.S.
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